Central nervous system EBV lymphoproliferative disorder in a patient with rhabdomyosarcoma

Kentaro Nakashima; Yuichi Kodama; Takuro Nishikawa; Miho Nishimura; Nobuhiro Ito; Reiji Fukano; Yuko Nomura; Tetsuya Ueba; Tooru Inoue; Koichi Oshima; Jun Okamura; Jiro Inagaki

doi:10.1111/ped.12812

Central nervous system EBV lymphoproliferative disorder in a patient with rhabdomyosarcoma

Pediatr Int. 2016 May;58(5):388-390. doi: 10.1111/ped.12812. Epub 2016 Jan 6.

Authors

Affiliations

¹ Department of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan.
² Department of Pediatrics, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
³ Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
⁴ Department of Neurosurgery, Kochi Medical School, Kochi, Japan.
⁵ Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan.

PMID: 26738608
DOI: 10.1111/ped.12812

Abstract

Epstein-Barr virus associated lymphoproliferative disorder (EBV-LPD) occurs in patients with immunodeficiency, but it has not been well described in patients who have received chemotherapy for solid tumors. We describe a child with rhabdomyosarcoma who developed isolated central nervous system (CNS) EBV-LPD during combination chemotherapy with vincristine, actinomycin D and cyclophosphamide. The patient was treated with high-dose methotrexate (HD-MTX) for CNS EBV-LPD and then treated with rituximab in addition to HD-MTX because of the emergence of LPD in the liver. I.v. rituximab combined with HD-MTX might be effective therapy for CNS EBV-LPD.

Keywords: Epstein-Barr virus-associated lymphoproliferative disorder; central nervous system; high-dose methotrexate; rhabdomyosarcoma; rituximab.

Publication types

Case Reports